Abstract 105P
Background
PD-1 blockade has brought impressive response rate in pts with dMMR/MSI-H solid tumors compared with chemotherapy. QL1604, a novel anti-PD-1 antibody, has shown good safety and preliminary anti-tumor activity in advanced solid tumors in the phase I study.
Methods
This single-arm, phase II study (NCT04326829) evaluated the efficacy and safety of QL1604 in pts with unresectable or metastatic dMMR/MSI-H solid tumors from 38 clinical sites across China. Pts received QL1604 (200 mg, iv, Q3W; 3 mg/kg for pts with body weight <40 kg, Q3W), until disease progression, intolerance, withdrawal of consent, or up to 2 years (whichever occurred first). The primary endpoint was objective response rate (ORR) assessed by independent radiological review committee (IRRC) per RECIST 1.1.
Results
From Jun 19, 2020 to Jan 12, 2023, 120 pts with dMMR/MSI-H solid tumors were enrolled, of whom 80 (66.7%) pts had colorectal cancer (CRC), 18 (15.0%) pts had gastric cancer, and 22 (18.3%) had other solid tumors. A total of 97.5% pts had stage IV disease at study entry, and the median prior therapy lines was 2.0 (range, 0-6). With median follow-up of 13.59 mo (range, 0.5–35.3 mo), the ORR and DCR per IRRC were 55/120 (45.8%; 95% CI: 36.7%–55.2%) and 93/120 (77.5%, 95% CI: 69.0%–84.6%), respectively, with 11 (9.2%) complete response (CR) and 44 (36.7%) partial response. In the CRC subgroup, the ORR and DCR per IRRC were 34/80 (42.5%, 95% CI: 31.5%–54.1%) and 62/80 (77.5%, 95% CI: 66.8%–86.1%), respectively. Overall, median duration of response (DoR) was not reached, with 6-mo and 12-mo DoR rates of 100% (95% CI: NE–NE) and 97.4% (95% CI: 83.2%–99.6%), respectively. Median progression-free survival and median overall survival were not reached. TEAEs of any grade occurred in 117 (97.5%) pts. The most frequent treatment-related adverse events (TRAEs) of any grade and grade ≥3 TRAEs were both anemia, with incidence of 25.8% and 5.0%, respectively. No QL1604-related death occurred.
Conclusions
QL1604 showed promising efficacy with high response rate and durable response and tolerable toxicity in pts with dMMR/MSI-H solid tumors.
Clinical trial identification
NCT04326829.
Editorial acknowledgement
Legal entity responsible for the study
Qilu Pharmaceutical Co., Ltd.
Funding
Qilu Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract